info@seagull-health.com
SeagullHealth
语言:
search

Cabotegravir(Vocabria)

Names
卡替拉韦,卡博特韦
Indicatons
Short-term oral treatment of HIV-1 infection (in combination with rilpivirine) and short-term oral pre-exposure...
Price:
Manufacturer:
ViiV Healthcare
Dosage form:
TABLET
Validity period:
24 months

Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.

Vocabria(Cabotegravir) Instructions:Uses,Dosage, Side Effects

VOCABRIA (cabotegravir) is an HIV-1 integrase strand transfer inhibitor (INSTI) initially approved in the U.S. in 2021. It is formulated as 30 mg tablets for oral use and is designed for short-term applications, either as part of a combination regimen for treating HIV-1 infection or as pre-exposure prophylaxis (PrEP) to reduce the risk of acquiring HIV-1. 

The drug is often used as a lead-in to assess patient tolerance before transitioning to long-acting injectable formulations like CABENUVA or APRETUDE, ensuring safer and more personalized care.

Generic name
Cabotegravir(Vocabria)
English name
Cabotegravir
Alternative Names
卡替拉韦,卡博特韦
Drug prices
Indications

HIV-1 Treatment: Indicated in combination with EDURANT (rilpivirine) for the short-term treatment of HIV-1 infection in virologically suppressed adults and adolescents (≥12 years, ≥35 kg) with no history of treatment failure and no known resistance to either drug. Used as an oral lead-in to assess tolerability prior to initiating CABENUVA injections or as oral therapy to cover planned missed injections.

HIV-1 PrEP: Indicated for short-term pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 in at-risk adults and adolescents (≥35 kg) with a confirmed negative HIV-1 status. Used as an oral lead-in prior to APRETUDE injections or to cover a planned missed injection.

Therapeutic Target
HIV-1 Integrase
Active Ingredients
Cabotegravir
Dosage Form
TABLET
Specifications
30mg * 30 Tablets/Box
Dosage and Administration

HIV-1 Treatment: One 30 mg VOCABRIA tablet taken orally once daily with one 25 mg EDURANT tablet, administered with a meal. For oral lead-in, the duration is approximately 1 month (at least 28 days). To replace missed CABENUVA injections, oral therapy is used for up to 2 months.

HIV-1 PrEP: One 30 mg VOCABRIA tablet taken orally once daily. For oral lead-in, the duration is approximately 1 month (at least 28 days). To replace a missed APRETUDE injection, oral therapy is initiated approximately 2 months after the last injection.

Antacids containing polyvalent cations should be administered at least 2 hours before or 4 hours after VOCABRIA.

    Recommended articles
    Related articles
    How to Purchase Cabotegravir
    Cabotegravir is an HIV-1 integrase strand transfer inhibitor (INSTI) used for the treatment of HIV-1 and pre-exposure prophylaxis (PrEP) against HIV-1.How to Purchase CabotegravirOverseas Purchase(1) ...
    Indications of Cabotegravir
    Cabotegravir is an HIV-1 integrase strand transfer inhibitor (INSTI) developed by ViiV Healthcare. As a significant advancement in the field of antiretroviral therapy, Cabotegravir offers two dosage f...
    Precautions for Cabotegravir Administration
    Cabotegravir is an HIV-1 integrase strand transfer inhibitor (INSTI). As the active ingredient in VOCABRIA, it can be used both for the treatment of HIV-1 infection and pre-exposure prophylaxis (PrEP)...
    Precautions for Cabotegravir Administration
    Cabotegravir is an HIV-1 integrase strand transfer inhibitor (INSTI). As the active ingredient in VOCABRIA, it can be used both for the treatment of HIV-1 infection and pre-exposure prophylaxis (PrEP)...
    What Are the Side Effects of Cabotegravir?
    Cabotegravir is an HIV-1 integrase strand transfer inhibitor (INSTI) used for the treatment of HIV-1 infection and pre-exposure prophylaxis (PrEP). As the active ingredient in VOCABRIA (cabotegravir t...
    What Are the Side Effects of Cabotegravir?
    Cabotegravir is an HIV-1 integrase strand transfer inhibitor (INSTI) used for the treatment of HIV-1 infection and pre-exposure prophylaxis (PrEP) against HIV-1. As the main active ingredient in VOCAB...
    New Drugs
    Infigratinib(Truseltiq)
    Infigratinib(Truseltiq)
    Treatment of previously treated, unresectable locally advanced or metastatic...
    Opicapone(Ongentys)
    Opicapone(Ongentys)
    Adjunctive treatment to levodopa/carbidopa for reducing "off" episodes in...
    Deflazacort(Emflaza)
    Deflazacort(Emflaza)
    Treatment of Duchenne muscular dystrophy (DMD) in patients aged 2 years and...
    Faricimab-svoa(Vabysmo)
    Faricimab-svoa(Vabysmo)
    Treatment of neovascular age-related macular degeneration, diabetic macular...
    Counselling Service
    Global Drug Search
    Clinical Research Recruitment
    Overseas Medical Treatment
    Remote Consultations
    Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
    Submit
    Business
    • Core products
    • Antitumor drugs
    • General drug
    • Antiviral drugs
    • Biological agents
    Contact Us 
    • mailbox:info@lucius.la
    Welcome to consult
    ucius Pharmaceuticals (Lao) Co.,Ltd All rights reserved